Piper Jaffray analyst Christopher Raymond reiterated a Neutral rating and $305.00 price target on Biogen (NASDAQ: BIIB) after Wolters Kluwer ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE